Back to top

crispr: Archive

Sundeep Ganoria

CRISPR Therapeutics Stock Falls 7% in Two Weeks: Time to Hold or Sell?

The decline in CRSP's share price could be due to the beating the drug/biotech sector has been taking in the past couple of months, resulting from pipeline setbacks and guidance cuts.

VRTXNegative Net Change BEAMNegative Net Change EDITPositive Net Change CRSPNegative Net Change